Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Vaidyane Ayurved Laboratories's Debt-to-Equity or its related term are showing as below:
NSE:MADHAVBAUG'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 0.99
Current: 0.03
During the past 8 years, the highest Debt-to-Equity Ratio of Vaidyane Ayurved Laboratories was 0.99. The lowest was 0.00. And the median was 0.03.
NSE:MADHAVBAUG's Debt-to-Equity is ranked better than 88.94% of 814
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs NSE:MADHAVBAUG: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Vaidyane Ayurved Laboratories Debt-to-Equity Related Terms
Vaidyane Ayurved Laboratories Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vaidyane Ayurved Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaidyane Ayurved Laboratories Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vaidyane Ayurved Laboratories's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Vaidyane Ayurved Laboratories's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a Debt-to-Equity of 0.03 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vaidyane Ayurved Laboratories and its competitors. This is near median its historical median of 0.03. According to the industry distribution chart, Vaidyane Ayurved Laboratories ranks #90 out of 814 companies in the Drug Manufacturers industry, placing it in the top 11.1%.
Is Vaidyane Ayurved Laboratories' Debt-to-Equity too high?
Vaidyane Ayurved Laboratories' current Debt-to-Equity of 0.03 is near median its 10-year median of 0.03. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Vaidyane Ayurved Laboratories' value of 0.03 is 89.3% below this industry median. Based on the distribution chart, Vaidyane Ayurved Laboratories ranks #90 out of 814 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vaidyane Ayurved Laboratories ranks #90 out of 814 companies for Debt-to-Equity. This places Vaidyane Ayurved Laboratories in the top 11% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.28. Vaidyane Ayurved Laboratories' value of 0.03 is 89.3% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.28, Vaidyane Ayurved Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaidyane Ayurved Laboratories's current Debt-to-Equity of 0.03 is 89.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vaidyane Ayurved Laboratories and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaidyane Ayurved Laboratories's current Debt-to-Equity is 0.03, which is near median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Possible Value Trap. The stock's GF Value™ is ₹228.32, compared to a current price of ₹159.35 — trading 30.2% below its estimated fair value. The current Debt-to-Equity is 0.03, which is near median its 10-year median of 0.03 and 89.3% below the Drug Manufacturers industry median of 0.28. Vaidyane Ayurved Laboratories' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current Debt-to-Equity is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued.
The current stock price of ₹159.35 is trading 30.2% below its estimated GF Value™ of ₹228.32.
GuruFocus considers Vaidyane Ayurved Laboratories to be Possible Value Trap.
Key valuation signals for NSE:MADHAVBAUG:
Debt-to-Equity: 0.03 (near median its 10-year median of 0.03)
GF Value™: ₹228.32 vs. price of ₹159.35 (30.2% below fair value)
Industry Position: 89.3% below the Drug Manufacturers median (#90 of 814)
No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
73GF Score
Get the complete analysis for NSE:MADHAVBAUG
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MADHAVBAUG has been successfully added to your 
